The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer
Adult
Male
Mice, Inbred BALB C
Epithelial-Mesenchymal Transition
Lung Neoplasms
Blotting, Western
Cystic Fibrosis Transmembrane Conductance Regulator
Down-Regulation
Mice, Nude
Kaplan-Meier Estimate
Middle Aged
Immunohistochemistry
Disease-Free Survival
3. Good health
Mice
03 medical and health sciences
0302 clinical medicine
Carcinoma, Non-Small-Cell Lung
Biomarkers, Tumor
Animals
Humans
Female
Aged
DOI:
10.3892/ijo.2015.2921
Publication Date:
2015-03-06T13:33:14Z
AUTHORS (16)
ABSTRACT
An increased risk of non-small cell lung cancer (NSCLC) in cystic fibrosis (CF) patients and carriers CF transmembrane conductance regulator (CFTR) mutations has been proposed. However, the role CFTR remains controversial. In present study, expression was assessed 165 NSCLC tumors 22 normal samples with validation an independent series 131 samples. The effect gain loss on malignant behavior examined. manipulation tumor metastasis examined a mouse model. Expression downregulated (p=0.041). Low correlated advanced stage (p<0.001) lymph node (p=0.009). significantly associated poor prognosis (overall survival: 45 vs. 36 months, p<0.0001; progression-free 41 30 p=0.007). Knockdown cells enhanced (epithelial-mesenchymal transition, invasion migration); contrast, overexpression suppressed progression vitro vivo. tumor-suppressing inhibition multiple uPA/uPAR-mediated traits culture. These results show that plays suggest may serve as novel indicator for predicting adverse patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (43)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....